Previous 10 | Next 10 |
Biogen ( BIIB ) - The company announced interim results from a phase 1/2 study of tofersen (antisense oligonucleotide) being studied for the treatment of amyotrophic lateral sclerosis ((ALS)). Data was sufficiently encouraging to support initiation of phase 3 study in SOD1-ALS patients and ...
You don't make money when you buy stocks. And you don't make money when you sell stocks. You make money by waiting - The Dhando Investor (Mohnish Pabrai) According to Integrated BioSci Investing, being "opportunistic" is one of the requisites to successful capital allocation. Stellar inves...
Heron Therapeutics (NASDAQ: HRTX ) -24% after FDA rejects application for pain med HTX-011. More news on: Heron Therapeutics, Inc., Nabriva Therapeutics plc, CM Seven Star Acquisition Corporation, Stocks on the move, Read more ...
Staffing 360 Solutions (NASDAQ: STAF ) +22% on Q1 earnings . More news on: Staffing 360 Solutions, Inc., Nu Skin Enterprises, Inc., Enphase Energy, Inc., Stocks on the move, Read more ...
Heron Therapeutics (NASDAQ: HRTX ) has received a CRL from the FDA regarding its marketing application for HTX-011 for the management of postoperative pain. More news on: Heron Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , May 1, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that ...
We think Heron ( HRTX ) has a very good chance of approval by the FDA by the April 30, 2019 due date for its non-opioid pain med HTX-011. This would be good for society in our fight against the opioid crisis. Furthermore, it could be rewarding for investors too, since this derisking event if t...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio...
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 PR Newswire SAN DIEGO , July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company...
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...